A modular, phase I, open-label, multicenter study to evaluate the safety, tolerability, cellular kinetics, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD0120, a dual-targeting autologous chimeric antigen receptor T-cell (CAR-T) therapy directed against BCMA and CD19 in participants with multiple myeloma (DURGA-2)